238 related articles for article (PubMed ID: 18459103)
1. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
Teichert F; Verschoyle RD; Greaves P; Edwards RE; Teahan O; Jones DJ; Wilson ID; Farmer PB; Steward WP; Gant TW; Gescher AJ; Keun HC
Prostate; 2008 Jul; 68(10):1035-47. PubMed ID: 18459103
[TBL] [Abstract][Full Text] [Related]
2. Silibinin feeding alters the metabolic profile in TRAMP prostatic tumors: 1H-NMRS-based metabolomics study.
Raina K; Serkova NJ; Agarwal R
Cancer Res; 2009 May; 69(9):3731-5. PubMed ID: 19366793
[TBL] [Abstract][Full Text] [Related]
3. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
5. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
Cao MD; Döpkens M; Krishnamachary B; Vesuna F; Gadiya MM; Lønning PE; Bhujwalla ZM; Gribbestad IS; Glunde K
NMR Biomed; 2012 Sep; 25(9):1033-42. PubMed ID: 22279038
[TBL] [Abstract][Full Text] [Related]
6. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Glunde K; Jie C; Bhujwalla ZM
Cancer Res; 2004 Jun; 64(12):4270-6. PubMed ID: 15205341
[TBL] [Abstract][Full Text] [Related]
7. Lobe-specific proteome changes in the dorsal-lateral and ventral prostate of TRAMP mice versus wild-type mice.
Zhang J; Wang L; Zhang Y; Li L; Higgins L; Lü J
Proteomics; 2011 Jun; 11(12):2542-9. PubMed ID: 21598396
[TBL] [Abstract][Full Text] [Related]
8. Dietary tomato and lycopene impact androgen signaling- and carcinogenesis-related gene expression during early TRAMP prostate carcinogenesis.
Wan L; Tan HL; Thomas-Ahner JM; Pearl DK; Erdman JW; Moran NE; Clinton SK
Cancer Prev Res (Phila); 2014 Dec; 7(12):1228-39. PubMed ID: 25315431
[TBL] [Abstract][Full Text] [Related]
9. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Jain AK; Raina K; Agarwal R
Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
[TBL] [Abstract][Full Text] [Related]
10. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
11. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.
Grinde MT; Skrbo N; Moestue SA; Rødland EA; Borgan E; Kristian A; Sitter B; Bathen TF; Børresen-Dale AL; Mælandsmo GM; Engebraaten O; Sørlie T; Marangoni E; Gribbestad IS
Breast Cancer Res; 2014 Jan; 16(1):R5. PubMed ID: 24447408
[TBL] [Abstract][Full Text] [Related]
12. Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: a multiparametric magnetic resonance study.
Raina K; Ravichandran K; Rajamanickam S; Huber KM; Serkova NJ; Agarwal R
Cancer Prev Res (Phila); 2013 Jan; 6(1):40-50. PubMed ID: 23213071
[TBL] [Abstract][Full Text] [Related]
13. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
14. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Al-Saffar NM; Jackson LE; Raynaud FI; Clarke PA; Ramírez de Molina A; Lacal JC; Workman P; Leach MO
Cancer Res; 2010 Jul; 70(13):5507-17. PubMed ID: 20551061
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism.
Singh KB; Kim SH; Hahm ER; Pore SK; Jacobs BL; Singh SV
Carcinogenesis; 2018 May; 39(6):826-837. PubMed ID: 29668854
[TBL] [Abstract][Full Text] [Related]
16. Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model.
Touma SE; Perner S; Rubin MA; Nanus DM; Gudas LJ
Biochem Pharmacol; 2009 Nov; 78(9):1127-38. PubMed ID: 19549509
[TBL] [Abstract][Full Text] [Related]
17. Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.
Mazzoleni S; Jachetti E; Morosini S; Grioni M; Piras IS; Pala M; Bulfone A; Freschi M; Bellone M; Galli R
Stem Cells Transl Med; 2013 Sep; 2(9):678-89. PubMed ID: 23884639
[TBL] [Abstract][Full Text] [Related]
18. Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model.
Costello LC; Franklin RB; Zou J; Feng P; Bok R; Swanson MG; Kurhanewicz J
Cancer Biol Ther; 2011 Dec; 12(12):1078-84. PubMed ID: 22156800
[TBL] [Abstract][Full Text] [Related]
19. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells.
Ackerstaff E; Pflug BR; Nelson JB; Bhujwalla ZM
Cancer Res; 2001 May; 61(9):3599-603. PubMed ID: 11325827
[TBL] [Abstract][Full Text] [Related]
20. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
